Clinical Question How to choose the drugs of adjuvant therapy for nonsmall-cell lung cancer(NSCLC)patients harboring driver gene mutation?Recommendations Recommendation 1:We suggest osimertinib(80 mg)adjuvant therapy ...Clinical Question How to choose the drugs of adjuvant therapy for nonsmall-cell lung cancer(NSCLC)patients harboring driver gene mutation?Recommendations Recommendation 1:We suggest osimertinib(80 mg)adjuvant therapy in stage Ib–IIIa EGFR-positive(Ex19del or L858R)NSCLC patients after surgery.According to the results of the ADAURA study,the benefit of osimertinib administration increases with advancing tumor stage.(Strong recommendation,high certainty of evidence)展开更多
文摘Clinical Question How to choose the drugs of adjuvant therapy for nonsmall-cell lung cancer(NSCLC)patients harboring driver gene mutation?Recommendations Recommendation 1:We suggest osimertinib(80 mg)adjuvant therapy in stage Ib–IIIa EGFR-positive(Ex19del or L858R)NSCLC patients after surgery.According to the results of the ADAURA study,the benefit of osimertinib administration increases with advancing tumor stage.(Strong recommendation,high certainty of evidence)
